nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.02.2016 | original report

TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer

verfasst von: N. Chilingirova, Z. Hammoudeh, L. Balabanski, S. Ivanov, R. Vazharova, D. Nikolova, Prof. G. Kurteva, D. Toncheva, P. Chilingirov

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Lung cancer is the most common cause of cancer death worldwide, and its prognosis and treatment response rate as well as the survival rate remain poor. In our study, we performed next generation sequencing (NGS) with cancer panel (Illumina) for 19 Bulgarian patients with both non-small cell lung cancer (NSCLC; 18 patients) and neuroendocrine tumor (1 patient) and focused on common polymorphisms which define proven or reported sensitivity to platinum-based therapy. We report reference SNP (rs)1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs1799793, and rs13181 (ERCC2) single nucleotide polymorphism variants which have been detected in our patients in homozygous and/or heterozygous state. Therefore, we give important information to confirm the role of those polymorphisms in tumor resistance and recurrence after chemotherapy treatment. The results reveal that TruSight Cancer Panel could be a useful clinical tool for determining pharmacogenetic variants associated with the effect of chemotherapy.

Vorheriger Artikel Treatment of elderly patients with advanced urological cancer

Nächster Artikel Intensive care for cancer patients

Centers for Disease Control and Prevention. Compressed Mortality File 1999–2012, Series 20 No. 2R; 2014.

Cancer Incidence in Bulgaria. 2012. Z. Valerianova, N. Dimitrova, S. Tonev, M. Vukov, p. 35.

Sculier JP, Berghmans T, Meert AP. Advances in target therapy in lung cancer. Eur Respir Rev. 2015;24:23–9.CrossRefPubMed

Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res. 2015;7:75–82.CrossRefPubMedPubMedCentral

Ai X, Shen S, Shen L, Lu S. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. Biochimie. 2015;112:111–20.CrossRefPubMed

Zimmermann S, Peters S. Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. Cancer Metastasis Rev. 2015:1–10.

Rousseau B, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5. doi:10.1038/srep10356.

Lampaki S, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. J Cancer. 2015;6(6):568–74.CrossRefPubMedPubMedCentral

Reck M, Von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.CrossRefPubMed

10.

Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253–63.CrossRefPubMed

11.

Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11(1):31–46.CrossRefPubMed

12.

Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.CrossRefPubMed

13.

Kan Z, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869–73.CrossRefPubMed

14.

Wagle N, et al. Dissecting therapeutic resistance to RAF Inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–96.CrossRefPubMedPubMedCentral

15.

Tibaldi C, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.CrossRefPubMed

16.

Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13(3):440–53.CrossRefPubMedPubMedCentral

17.

Dumont P, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.CrossRefPubMed

18.

Liu L, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793–800.CrossRefPubMed

19.

Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21–49.CrossRef

20.

Ogle KS, Swanson GM, Woods N, et al. Cancer and comorbidity. Cancer. 2000;88:653–63.CrossRefPubMed

21.

Johnson N, et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 2007;16(9):1051–7.CrossRefPubMed

22.

Kim J, et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol. 2009;64(2):355–60.CrossRefPubMed

23.

Parmar S, et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2013;13(2):181–8.CrossRefPubMed

24.

Liu W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007;13(22 Pt 1):6788–95.CrossRefPubMed

25.

Sullivan I, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–6.CrossRefPubMed

26.

Lu J, et al. Correlation of rs1799793 polymorphism in ERCC2 and the clinical response to platinum-based chemotherapy in patients with triple negative breast cancer. Int J Clin Exp Med. 2015;8(2):2934–8.PubMedPubMedCentral

27.

Boige V, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28(15):2556–64.CrossRefPubMed

28.

Giovannetti E, et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011;12(12):1641–52.CrossRefPubMed

29.

Wei S.-z., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.CrossRefPubMed

Titel: TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer
verfasst von: N. Chilingirova
Z. Hammoudeh
L. Balabanski
S. Ivanov
R. Vazharova
D. Nikolova
Prof. G. Kurteva
D. Toncheva
P. Chilingirov
Publikationsdatum: 01.02.2016
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-015-0244-2

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Intensive care for cancer patients

Never too old to treat cancer?

Erratum to: A review on biomolecular basis of the role of psychological stress in the development and progression of cancer

New approaches in graft versus host disease (GvHD) management

Open Access publizieren in „memo – magazine of european medical oncology“

Treatment of elderly and very old patients with AML